Adherex Technologies Inc.
TSX : AHX
AMEX : ADH

Adherex Technologies Inc.

October 12, 2006 08:00 ET

Adherex to Hold Corporate Update Conference Call Today

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(CCNMatthews - Oct. 12, 2006) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, announced today that it will hold a corporate update conference call on Thursday, October 12, 2006 at 10 a.m. EST. Adherex's Chairman and CEO Dr. William P. Peters will host the call.

To listen to a live or archived version of the audio webcast, which will include a slide presentation, investors should log on to the Adherex website (www.adherex.com) where a link to the call will be available. Adherex's corporate update conference call can also be heard by dialing (800) 289-0494 in the U.S. and Canada and (913) 981-5520 for international callers (passcode 4728549). A telephone replay will be available starting at 1 p.m. EST on October 12, 2006 and ending at midnight EST on Tuesday, October 17, 2006. To access the telephone replay, dial (888) 203-1112 if calling from the U.S. or Canada or (719) 457-0820 from international locations. Please refer to replay passcode 4728549.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.

Contact Information

  • Adherex Technologies Inc.
    Melissa Matson
    Director, Corporate Communications
    (919) 484-8484
    matsonm@adherex.com